B+
Bull case
25%
Probability
Target price
$42.00
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
KEQU
Kewaunee ScientificBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
50%
Probability
Target price
$33.25
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$26.25
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-10
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+59.2
Score
AI commentary
The primary earnings release supports a negative initial read because revenue and profitability declined materially, partly offset by sequential backlog growth, international margin mix, cost controls, and debt reduction. The packet does not provide a verified T+1 price reaction, consensus surprise, analyst target changes, estimate revisions, social coverage, options skew, short interest, or employee-review data; the zero-valued unavailable sentiment fields are placeholders rather than neutral evidence. Low coverage warrants cautious monitoring rather than a strong directional call.
RankAlpha Sentiment Codex - 2026-09-10
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30catalystFirst-quarter earnings resetHigh impact
Fiscal Q1 2027 sales declined 6.7% year over year to $66.32 million, diluted EPS fell to $0.58 from $1.04, and EBITDA declined to $4.53 million from $6.32 million. Lower LPG manufacturing volumes and challenging life-sciences conditions leave near-term sentiment tilted negative, although some corporate compensation expense was identified as nonrecurring [#SEC-8K-2026-09-09].
2026-12-09eventBacklog conversion and demand checkHigh impact
Backlog improved sequentially to $169.0 million at July 31 from $165.9 million at April 30, but remained below $205.0 million a year earlier. The next operating update should clarify whether education strength and international project mix can offset continued life-sciences weakness [#SEC-8K-2026-09-09].
2027-04-30catalystEfficiency and balance-sheet executionHigh impact
Cost management and operating efficiencies partially mitigated lower LPG volumes, while long-term debt excluding the sale-leaseback obligation declined to $13.8 million from $15.1 million during the quarter. Sustained debt reduction and improved volume leverage could rebuild earnings durability [#SEC-8K-2026-09-09].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-10 • Updated nightlySource: Internal modelMethodology